MDWD
MediWound Ltd. (NASDAQ)
Healthcare — Biotechnology
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Price History
Fundamentals
| Market Cap | $190.47M |
| P/E Ratio (TTM) | - |
| Forward P/E | -6.68 |
| EPS (TTM) | $-2.26 |
| Dividend Yield | - |
| Profit Margin | -180.30% |
| Revenue Growth | -62.70% |
| ROE | -71.82% |
| Debt/Equity | 19.62 |
| Recommendation | None |
| Analyst Target | $30.17 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 62.9 |
| Beta | 0.15 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $21.26 |
| 52-Week Low | $13.54 |
| 50-Day Avg | $15.50 |
| 200-Day Avg | $17.20 |
| Avg Volume | 91.5K |
| Volume | 64.3K |
Performance Analysis
NEUTRALMDWD presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:19 UTC
Back to Screener Export Report